Intermittent PI3Ka/ß/d Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy

Examination of gene expression level in tumor tissue or CD8T cell in vehicle, BAY1082439 (Single dose), BAY1082439 daily/intermittent treatment, BAY1082439 treatment release drug treatment group. Examination of gene expression level in CAP2 CAP8 PC3 and LNCaP cell line in vehicle or BAY1082439 treatment. Examination of gene expression level in spleen CD8T cell in vehicle or intermittent BAY1082439 treatment. Overall design: Examination of gene expression levels using RNA-seq. The Supplementary_data_1.xlsx was added to the records on Jan 10, 2022.